Northern Trust’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-346,261
Closed -$16.1M – 4582
2023
Q2
$16.1M Buy
346,261
+37,264
+12% +$1.29M ﹤0.01% 1739
2023
Q1
$8.85M Sell
308,997
-140
-0% -$4.15K ﹤0.01% 2100
2022
Q4
$9.6M Buy
309,137
+78,657
+34% +$2.57M ﹤0.01% 2038
2022
Q3
$4.67M Buy
230,480
+17,367
+8% +$316K ﹤0.01% 2535
2022
Q2
$3.31M Buy
213,113
+93,893
+79% +$1.61M ﹤0.01% 2774
2022
Q1
$2.28M Sell
119,220
-5,548
-4% -$99K ﹤0.01% 3034
2021
Q4
$3.16M Buy
+124,768
New +$3.66M ﹤0.01% 2984

Northern Trust's DICE Position: Q3 2023 in Review

Northern Trust sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 346,261 shares — an estimated $16.1M sold.

Northern Trust first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $16.1M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Northern Trust reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Northern Trust sold 346,261 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $16.1M.
  • Northern Trust first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Northern Trust's DICE Therapeutics, Inc. Common Stock position peaked at $16.1M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Northern Trust's 13F filing for Q3 2023, filed 13 Nov 2023.